ISRAEL – Israeli dairy start-up, Remilk has announced the appointment of Kobi Altman as Chief Financial Officer (CFO) and Secretary of the Board of Directors.

Kobi Altman has more than 25 years of executive financial experience in large global industrial organizations and he is currently the executive vice president and CFO of ICL Group Ltd, a leading global specialty minerals company.

Prior to ICL Group, he worked at Teva Pharmaceuticals Ltd for nine years, assuming various executive finance positions in the US and Israel.

Aviv Wolff, Remilk’s co-founder, and CEO says the skills Altman has are significant to contribute to Remilk’s team as they are accelerating growth and charge forward, to achieve their mission of disrupting the entire dairy industry with animal-free dairy.

Kobi Altman said: “I am thrilled to join Remilk’s fascinating journey. As we just announced our plans to build the world’s largest manufacturing facility of its kind in Kalundborg, Denmark.

“I’m truly excited to take part in the global revolution the company is leading, changing everything we know about dairy by crafting real dairy products that are environmentally friendly and animal-free to consumers around the world.”

Remilk produces dairy-identical milk proteins through precision fermentation where microorganisms are programmed to produce proteins, to ‘reinvent’ the category.

The company further says the technology will result in the production of products that are ‘indistinguishable’ in taste and function from traditional dairy, especially the yeast-based fermentation process that produces non-animal milk proteins for use in dairy products.

Last month, Remilk announced plans to build the world’s largest full-scale precision fermentation facility on more than 750,000 square feet of newly acquired land within The Symbiosis project, a pioneering sustainable industrial ecosystem, in Kalundborg, Denmark.

This facility will produce beta-lactoglobulin, which is the major whey protein of cow and sheep’s milk, as well as casein proteins alpha 1, alpha 2, beta, and kappa.

The company is also considering producing alpha-lactalbumin which is the main serum protein of human milk and is also present in cow’s milk.

By 2035, every tenth portion of meat, eggs, and dairy eaten around the globe is very likely to be alternative,” according to a new report from Boston Consulting Group and Blue Horizon Corporation.

The report further predicts that alternative proteins could account for 11% (US$290bn) of the market by 2035 in comparison to 2% in 2020. 

According to Remilk, its dairy products require a fraction of Earth’s precious resources and its manufacturing process emits up to 97% less carbon dioxide compared to the traditional dairy industry, a huge step towards fulfilling the UN’s goal of achieving net-zero emissions by 2050.

Liked this article? Subscribe to Food Business Africa News, our regular email newsletters with the latest news insights from Africa and the World’s food and agro industry. SUBSCRIBE HERE.